Connor Clark & Lunn Investment Management Ltd. Has $5.19 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Connor Clark & Lunn Investment Management Ltd. decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 12.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 682,324 shares of the biotechnology company's stock after selling 100,340 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.33% of BioCryst Pharmaceuticals worth $5,186,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BCRX. Deerfield Management Company L.P. Series C grew its position in shares of BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company's stock worth $50,279,000 after buying an additional 3,140,804 shares during the period. Kynam Capital Management LP raised its holdings in BioCryst Pharmaceuticals by 41.9% in the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company's stock worth $33,160,000 after purchasing an additional 1,927,491 shares during the period. Rice Hall James & Associates LLC boosted its position in shares of BioCryst Pharmaceuticals by 4.0% during the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock worth $16,444,000 after purchasing an additional 84,102 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of BioCryst Pharmaceuticals by 528.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company's stock valued at $6,874,000 after buying an additional 935,132 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in BioCryst Pharmaceuticals by 12.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company's stock worth $4,795,000 after buying an additional 86,249 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on BCRX shares. Royal Bank of Canada reissued an "outperform" rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. StockNews.com raised shares of BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, August 6th. Needham & Company LLC restated a "buy" rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. JMP Securities increased their target price on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a "market outperform" rating in a report on Tuesday, August 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $15.60.

BioCryst Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ:BCRX traded up $0.11 during midday trading on Friday, hitting $7.60. The stock had a trading volume of 1,977,442 shares, compared to its average volume of 2,477,516. The company has a market cap of $1.57 billion, a P/E ratio of -12.46 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.88. The business's 50-day simple moving average is $7.66 and its 200-day simple moving average is $7.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. The firm's revenue for the quarter was up 35.1% on a year-over-year basis. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.